Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Free Cash Flow (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Free Cash Flow for 11 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 59.6% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.0 million through Dec 2025, down 10.12% year-over-year, with the annual reading at -$12.0 million for FY2025, 10.12% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$1.9 million at Marker Therapeutics, up from -$2.7 million in the prior quarter.
  • The five-year high for Free Cash Flow was $2.4 million in Q2 2022, with the low at -$14.6 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$4.5 million, with a median of -$4.4 million recorded in 2022.
  • The sharpest move saw Free Cash Flow skyrocketed 135.31% in 2022, then plummeted 328.47% in 2025.
  • Over 5 years, Free Cash Flow stood at -$6.9 million in 2021, then soared by 41.3% to -$4.1 million in 2022, then skyrocketed by 41.96% to -$2.4 million in 2023, then plummeted by 98.65% to -$4.7 million in 2024, then soared by 59.6% to -$1.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$1.9 million, -$2.7 million, and -$1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.